How Will the Market React to Cardiff Oncology Inc (CRDF) Stock Getting a Bullish Rating

Overall market sentiment has been high on Cardiff Oncology Inc (CRDF) stock lately. CRDF receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Cardiff Oncology Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRDF!

See Full CRDF Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CRDF Stock Today?

Cardiff Oncology Inc (CRDF) stock is trading at $5.73 as of 10:36 AM on Monday, Mar 25, a loss of -$0.12, or -2.07% from the previous closing price of $5.85. The stock has traded between $5.62 and $6.42 so far today. Volume today is less active than usual. So far 642,909 shares have traded compared to average volume of 3,025,622 shares.

More About Cardiff Oncology Inc

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias. Click Here to get the full Stock Report for Cardiff Oncology Inc stock.